Chamber and committees

The OCTAVE trial funded by the Medical Research Council (MRC) is a collaborative project involving the Universities of Birmingham, Glasgow, Oxford, Liverpool, Imperial College London and Leeds Teaching Hospitals NHS Trust. This research work is investigating the effectiveness of COVID-19 vaccines being used in the UK in 2021 in up to 5,000 people from certain clinically at-risk patient groups who have impaired immune system function through underlying disease or drug treatment.

Further information is available here:

• Vaccine responses studied in patients with impaired immune systems – UKRI
• University of Glasgow - Research - Coronavirus research - OCTAVE to study vaccine responses in patients with impaired immune systems .

The Joint Committee on Vaccination and Immunisation (JCVI) constantly review all published and unpublished data to inform vaccination policy recommendation. The JCVI have reviewed data already on this topic and will do so in an on-going basis.

The Scottish Government stays up-to-date on all national and international developments regarding COVID-19, and are continuing discussions on a 4 Nations basis regarding development and possible use of new COVID-19 vaccines.

The approval of medicines is a reserved matter and all approval is managed by the Medicines and Healthcare products Regulatory Agency (MHRA).

On 28 May, the MHRA approved the single-dose Janssen vaccine for use in the UK for adults aged 18 and over, and we anticipate receiving some stocks of the vaccine later this year. As with all new COVID-19 vaccines, we anticipate that the Joint Committee on Vaccination and Immunisation (JCVI) will provide a recommendation on how the Jansen vaccine should be deployed. The UK Vaccine Taskforce has secured 20M doses, of which Scotland will receive a proportionate share.

The Novavax vaccine is also reporting encouraging results from stage 3 clinical trials (90% efficacy in the US study). If the vaccine is successful in trials and the MHRA assesses it as appropriately safe and effective for use, the UK will be able to access 60 million doses and Scotland will receive a proportionate share. However the timetable for supply is not clear as the supplier requires to implement a significant increase in manufacturing capacity.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK agency responsible for the approval of both clinical trials in the UK and of marketing authorisations (licences) for new medicinal products.

The MHRA is aware that ivermectin, administered orally, is being studied for safety and efficacy in numerous clinical trials worldwide. This includes an exploratory study being conducted within the UK: https://clinicaltrials.gov/ct2/show/NCT04632706 . Potential new therapeutic approaches to COVID-19 are being tested through the UK-wide platform trials, including RECOVERY, PRINCIPLE and REMAP CAP. These trials are active in Scotland. The PRINCIPLE study is a UK-wide clinical trial led by the University of Oxford, evaluating potential treatments for COVID-19 including ivermectin.

The Scottish Government is closely monitoring all emerging evidence on the effectiveness of COVID-19 treatments and their clinical effectiveness in particular patient groups to ensure medicines with the greatest impact in treating COVID-19 are available for patients in Scotland.

The Scottish Government continue to meet and work collaboratively with the recognised representative body for community pharmacy contractors in Scotland, Community Pharmacy Scotland.

Discussions have included the pharmacy networks response to the COVID-19 pandemic, additional support provided to the community pharmacy teams in providing a safe working environment and access to mental health and wellbeing support. The delivery of current and development of future pharmaceutical care service to support the NHS recovery from the pandemic and the impact of the pandemic to the financial sustainability of pharmacy network and the Scottish Drug Tariff.

Officials have also met with NHS Board Directors of Pharmacy to discuss the provision of pharmaceutical care services.

Work to preserve and increase the stock of grey partridge has traditionally been led by shooting interests such as the Game and Wildlife Conservation Trust (GWCT).

GWCT lead on the PARTRIDGE project in the UK, supported by the EU via the Interreg North Sea Region programme. It show-cases how new and improved management solutions can improve biodiversity and ecosystem services at 10 demonstration sites across the region. There are two demonstration sites in Scotland at Balgonie Farm in Fife and Whitburgh Farms in East Lothian promoting land management techniques specifically to benefit grey partridge https://northsearegion.eu/partridge/ .

More widely, the protection of Scotland’s biodiversity is a key priority for the Scottish Government, and we are committed to doing more to safeguard our species and habitats. Our high level Statement of Intent on biodiversity, published in December 2020, signalled our ambitions for biodiversity in Scotland, and the development of a new post-2020 biodiversity strategy. We have committed £7 million to date to the Biodiversity Challenge Fund and recently launched a new £10 million Nature Restoration Fund to help finance projects that support nature recovery and address climate change. Action to restore biodiversity is also central to our Green Recovery from Covid-19.

At present we are awaiting Joint Committee on Vaccination and Immunisation (JCVI) advice on whether all those aged 12 to 15, and all 16 and 17 year olds should be offered COVID-19 vaccination – and once we have this we will be preparing policy guidance as to how we will operationalise this for Scotland. No 16-17 year olds outwith the previously identified JCVI priority groups will have vaccination prior to the pending JCVI advice.

The Scottish Government stepped in to take ownership, to ensure a viable future for the yard, its workforce and completion of the much needed vessels. The Scottish Government continues to work closely with the yard to explore all possible options to ensure a viable future for the business.

The Scottish Government are in contact with Ferguson Marine on a regular basis. The Ferguson Marine Board of Directors visited the yard on 3 June to discuss the Turnaround Directors update to the Scottish Parliament. The Board subsequently signed off the revised schedule in early June and this information was then shared with the Scottish Government.

MV Glen Sannox was launched in November 2017. For Hull 802, much of the outfitting will be carried out before launch, making the work more efficient. As a result 802 will weigh over 1,000 tonnes more than Glen Sannox, meaning the tide conditions will be critical. Detailed engineering analysis is required to balance the tide, launch arrangement and weight to find the most effective combination.

The Scottish Government microplastics monitoring programme began in 2013, and has undertaken annual surveys since that time. There have been nearly 400 locations sampled between 2013 and 2020. There is currently an insufficient data series to determine if a trend exists or to be able to say when a baseline may be determined. However annual surveys continue to gather data, in order to work toward determining a baseline and/or trends.